For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of targeted therapy?

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of targeted therapy?

For what specific solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of molecularly targeted therapy?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Yilong Wu, MD

Yilong Wu, MD

Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China